Charles Schwab’s Trevi Therapeutics TRVI Stock Holding History

Charles Schwab’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18M	Buy	965,402 +124,830	+15%	+$1.82M	﹤0.01%	1885
2026 Q1	$10M	Buy	840,572 +3,772	+0.5%	+$42.2K	﹤0.01%	2091
2025 Q4	$10.5M	Buy	836,800 +30,469	+4%	+$352K	﹤0.01%	2120
2025 Q3	$7.38M	Buy	806,331 +580,396	+257%	+$4.35M	﹤0.01%	2266
2025 Q2	$1.24M	Buy	225,935 +18,417	+9%	+$115K	﹤0.01%	2832
2025 Q1	$1.31M	Buy	207,518 +34,455	+20%	+$164K	﹤0.01%	2752
2024 Q4	$713K	Buy	173,063 +22,145	+15%	+$70.9K	﹤0.01%	3033
2024 Q3	$504K	Hold	150,918	–	–	﹤0.01%	3162
2024 Q2	$450K	Buy	150,918 +43,211	+40%	+$120K	﹤0.01%	3243
2024 Q1	$372K	Hold	107,707	–	–	﹤0.01%	3130
2023 Q4	$144K	Hold	107,707	–	–	﹤0.01%	3314
2023 Q3	$235K	Hold	107,707	–	–	﹤0.01%	3258
2023 Q2	$257K	Buy	107,707 +95,150	+758%	+$240K	﹤0.01%	3265
2023 Q1	$23.2K	Hold	12,557	–	–	﹤0.01%	3488
2022 Q4	$24.2K	Hold	12,557	–	–	﹤0.01%	3479
2022 Q3	$20K	Hold	12,557	–	–	﹤0.01%	3478
2022 Q2	$36K	Buy	+12,557	New	+$30.8K	﹤0.01%	3440

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Charles Schwab's TRVI Position: Q2 2026 in Review

Charles Schwab increased its Trevi Therapeutics (TRVI) stake by 15% in Q2 2026, buying an estimated $1.82M and bringing the position to 965,402 shares worth $18M. The position accounts for ﹤0.01% of the portfolio, ranked #1885.

Charles Schwab first reported a position in TRVI in Q2 2022 and has held it in 17 quarters since. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

Charles Schwab held 965,402 shares of Trevi Therapeutics worth $18M as of Q2 2026.
Charles Schwab bought 124,830 Trevi Therapeutics shares in Q2 2026, an estimated $1.82M.
Trevi Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #1885 holding.
Charles Schwab first reported a position in Trevi Therapeutics in Q2 2022 and has held it in 17 quarters since.
218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.